{
    "2018-09-10": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Shire's ADHD Portfolio Remains Strong Amid Competition",
                "features": {
                    "keywords": [
                        "Shire",
                        "ADHD",
                        "Portfolio",
                        "Strong",
                        "Competition"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Notable Monday Option Activity: JNJ, BA, QCOM",
                "features": {
                    "keywords": [
                        "Monday",
                        "Option",
                        "Activity",
                        "JNJ",
                        "BA",
                        "QCOM"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "industrials",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Ranks",
                        "Analysts'",
                        "Top",
                        "Dow",
                        "30",
                        "Picks"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Dow Analyst Moves: JNJ",
                "features": {
                    "keywords": [
                        "Dow",
                        "Analyst",
                        "Moves",
                        "JNJ"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Most Analysts Currently Call Boston Scientific a ‘Buy’",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Boston",
                        "Scientific",
                        "Buy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Week Ahead: Apple's Special Event, Mobile World Congress, US Inflation Data On Deck",
                "features": {
                    "keywords": [
                        "Week",
                        "Ahead",
                        "Apple",
                        "Special",
                        "Event",
                        "Mobile",
                        "World",
                        "Congress",
                        "US",
                        "Inflation",
                        "Data",
                        "Deck"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "economy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod",
                "features": {
                    "keywords": [
                        "Perrigo",
                        "OTC",
                        "Version",
                        "Diarrhea",
                        "Drug",
                        "Imodium",
                        "FDA",
                        "Nod"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis a Top Ranked SAFE Dividend Stock With 3.6% Yield",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Top",
                        "Ranked",
                        "SAFE",
                        "Dividend",
                        "Stock",
                        "Yield"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Highlights",
                        "Novartis",
                        "AstraZeneca",
                        "Merck",
                        "Pfizer",
                        "Johnson",
                        "&",
                        "Johnson"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}